178 related articles for article (PubMed ID: 26116360)
1. Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.
Yarar D; Lahdenranta J; Kubasek W; Nielsen UB; MacBeath G
Mol Cancer Ther; 2015 Sep; 14(9):2072-80. PubMed ID: 26116360
[TBL] [Abstract][Full Text] [Related]
2. Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model.
Curley MD; Sabnis GJ; Wille L; Adiwijaya BS; Garcia G; Moyo V; Kazi AA; Brodie A; MacBeath G
Mol Cancer Ther; 2015 Nov; 14(11):2642-52. PubMed ID: 26310543
[TBL] [Abstract][Full Text] [Related]
3. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
4. Systems biology driving drug development: from design to the clinical testing of the anti-ErbB3 antibody seribantumab (MM-121).
Schoeberl B; Kudla A; Masson K; Kalra A; Curley M; Finn G; Pace E; Harms B; Kim J; Kearns J; Fulgham A; Burenkova O; Grantcharova V; Yarar D; Paragas V; Fitzgerald J; Wainszelbaum M; West K; Mathews S; Nering R; Adiwijaya B; Garcia G; Kubasek B; Moyo V; Czibere A; Nielsen UB; MacBeath G
NPJ Syst Biol Appl; 2017; 3():16034. PubMed ID: 28725482
[TBL] [Abstract][Full Text] [Related]
5. HRG-β1-driven ErbB3 signaling induces epithelial-mesenchymal transition in breast cancer cells.
Kim J; Jeong H; Lee Y; Kim C; Kim H; Kim A
BMC Cancer; 2013 Aug; 13():383. PubMed ID: 23937725
[TBL] [Abstract][Full Text] [Related]
6. Heregulin-induced VEGF expression via the ErbB3 signaling pathway in colon cancer.
Yonezawa M; Wada K; Tatsuguchi A; Akamatsu T; Gudis K; Seo T; Mitsui K; Nagata K; Tanaka S; Fujimori S; Sakamoto C
Digestion; 2009; 80(4):215-25. PubMed ID: 19797898
[TBL] [Abstract][Full Text] [Related]
7. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
Awasthi S; Hamburger AW
J Cell Physiol; 2014 Nov; 229(11):1831-41. PubMed ID: 24692179
[TBL] [Abstract][Full Text] [Related]
8. Significance of integrin αvβ5 and erbB3 in enhanced cell migration and liver metastasis of colon carcinomas stimulated by hepatocyte-derived heregulin.
Yoshioka T; Nishikawa Y; Ito R; Kawamata M; Doi Y; Yamamoto Y; Yoshida M; Omori Y; Kotanagi H; Masuko T; Enomoto K
Cancer Sci; 2010 Sep; 101(9):2011-8. PubMed ID: 20626753
[TBL] [Abstract][Full Text] [Related]
9. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
Yang C; Liu Y; Lemmon MA; Kazanietz MG
Mol Cell Biol; 2006 Feb; 26(3):831-42. PubMed ID: 16428439
[TBL] [Abstract][Full Text] [Related]
10. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
Smirnova T; Zhou ZN; Flinn RJ; Wyckoff J; Boimel PJ; Pozzuto M; Coniglio SJ; Backer JM; Bresnick AR; Condeelis JS; Hynes NE; Segall JE
Oncogene; 2012 Feb; 31(6):706-15. PubMed ID: 21725367
[TBL] [Abstract][Full Text] [Related]
11. Neuregulin 1 expression is a predictive biomarker for response to AV-203, an ERBB3 inhibitory antibody, in human tumor models.
Meetze K; Vincent S; Tyler S; Mazsa EK; Delpero AR; Bottega S; McIntosh D; Nicoletti R; Winston WM; Weiler S; Feng B; Gyuris J; Weng Z
Clin Cancer Res; 2015 Mar; 21(5):1106-14. PubMed ID: 25542901
[TBL] [Abstract][Full Text] [Related]
12. An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Schoeberl B; Faber AC; Li D; Liang MC; Crosby K; Onsum M; Burenkova O; Pace E; Walton Z; Nie L; Fulgham A; Song Y; Nielsen UB; Engelman JA; Wong KK
Cancer Res; 2010 Mar; 70(6):2485-94. PubMed ID: 20215504
[TBL] [Abstract][Full Text] [Related]
13. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
14. Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer.
Sequist LV; Gray JE; Harb WA; Lopez-Chavez A; Doebele RC; Modiano MR; Jackman DM; Baggstrom MQ; Atmaca A; Felip E; Provencio M; Cobo M; Adiwijaya B; Kuesters G; Kamoun WS; Andreas K; Pipas JM; Santillana S; Cho BC; Park K; Shepherd FA
Oncologist; 2019 Aug; 24(8):1095-1102. PubMed ID: 30975923
[TBL] [Abstract][Full Text] [Related]
15. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
16. mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract][Full Text] [Related]
17. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
Tan M; Grijalva R; Yu D
Cancer Res; 1999 Apr; 59(7):1620-5. PubMed ID: 10197638
[TBL] [Abstract][Full Text] [Related]
18. Expression of heregulin alpha, erbB2, and erbB3 and their influences on proliferation of gastric epithelial cells.
Noguchi H; Sakamoto C; Wada K; Akamatsu T; Uchida T; Tatsuguchi A; Matsui H; Fukui H; Fujimori T; Kasuga M
Gastroenterology; 1999 Nov; 117(5):1119-27. PubMed ID: 10535875
[TBL] [Abstract][Full Text] [Related]
19. Isoliquiritigenin (ISL) inhibits ErbB3 signaling in prostate cancer cells.
Jung JI; Chung E; Seon MR; Shin HK; Kim EJ; Lim SS; Chung WY; Park KK; Park JH
Biofactors; 2006; 28(3-4):159-68. PubMed ID: 17473376
[TBL] [Abstract][Full Text] [Related]
20. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
